These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 24767862)

  • 1. BRAF/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis.
    Cornejo KM; Hutchinson L; Deng A; Tomaszewicz K; Welch M; Lyle S; Dresser K; Cosar EF
    Hum Pathol; 2014 Jun; 45(6):1213-20. PubMed ID: 24767862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.
    Peterson LM; Kipp BR; Halling KC; Kerr SE; Smith DI; Distad TJ; Clayton AC; Medeiros F
    Int J Gynecol Pathol; 2012 May; 31(3):195-205. PubMed ID: 22498935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors.
    Honecker F; Wermann H; Mayer F; Gillis AJ; Stoop H; van Gurp RJ; Oechsle K; Steyerberg E; Hartmann JT; Dinjens WN; Oosterhuis JW; Bokemeyer C; Looijenga LH
    J Clin Oncol; 2009 May; 27(13):2129-36. PubMed ID: 19289622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.
    Mathiak M; Rütten A; Mangold E; Fischer HP; Ruzicka T; Friedl W; Propping P; Kruse R
    Am J Surg Pathol; 2002 Mar; 26(3):338-43. PubMed ID: 11859205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
    Jessup CJ; Redston M; Tilton E; Reimann JD
    Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma.
    Rajan Kd A; Burris C; Iliff N; Grant M; Eshleman JR; Eberhart CG
    Am J Ophthalmol; 2014 Mar; 157(3):640-7.e1-2. PubMed ID: 24321472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer.
    Cesinaro AM; Ubiali A; Sighinolfi P; Trentini GP; Gentili F; Facchetti F
    Am J Dermatopathol; 2007 Aug; 29(4):351-8. PubMed ID: 17667167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer.
    Kawaguchi M; Yanokura M; Banno K; Kobayashi Y; Kuwabara Y; Kobayashi M; Nomura H; Hirasawa A; Susumu N; Aoki D
    Int J Oncol; 2009 Jun; 34(6):1541-7. PubMed ID: 19424571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms.
    Borie C; Colas C; Dartigues P; Lazure T; Rince P; Buhard O; Folliot P; Chalastanis A; Muleris M; Hamelin R; Mercier D; Oliveira C; Seruca R; Chadburn A; Leblond V; Barete S; Gaïdano G; Martin A; Gaulard P; Fléjou JF; Raphael M; Duval A
    Int J Cancer; 2009 Nov; 125(10):2360-6. PubMed ID: 19551857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy.
    Ponti G; Meschieri A; Pollio A; Ruini C; Manfredini M; Longo C; Mandel VD; Ciardo S; Tomasi A; Giannetti L; Pellacani G
    J Oral Pathol Med; 2015 Aug; 44(7):552-7. PubMed ID: 25213213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome.
    Entius MM; Keller JJ; Drillenburg P; Kuypers KC; Giardiello FM; Offerhaus GJ
    Clin Cancer Res; 2000 May; 6(5):1784-9. PubMed ID: 10815898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases.
    Boennelycke M; Thomsen BM; Holck S
    Pathol Res Pract; 2015 Jan; 211(1):78-82. PubMed ID: 25457183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunophenotypes and gene mutations in colorectal precancerous lesions and adenocarcinoma].
    Huang WT; Qiu T; Ling Y; Shi SS; Guo L; Zheng B; Lü N; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2013 Oct; 42(10):655-9. PubMed ID: 24433726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification.
    Parsons MT; Buchanan DD; Thompson B; Young JP; Spurdle AB
    J Med Genet; 2012 Mar; 49(3):151-7. PubMed ID: 22368298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
    Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
    Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.